Prevalence of chronic obstructive pulmonary disease (COPD) not diagnosed in a population with cardiovascular risk factors

Montserrat-Capdevila, Josep; Seminario, María Asunción; Godoy, Pere; Marsal, Josep Ramón; Ortega, Marta; Pujol, Jesús; Castañ, Maria Teresa; Alsedà, Miquel; Betriu, Àngels; Lecube, Albert; Portero, Manuel Aguilar; Purroy, Francisco; Valdivielso, José Manuel; Barbé, Ferrán

doi:10.1016/j.medcle.2018.09.006

Cited by 3 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 3% prevalence obtained in this study might respond to under-reporting in the primary care setting caused by mild symptomatology (most patients would be classified as GOLD stages1-2, with mMRC < 2 and CAT < 10) and under-recording of spirometry results. Experts believe that a significant number of patients remain undiagnosed [ 6 ]. The higher proportion of men than women (77.1% vs 22.9%, respectively) diagnosed with COPD is corroborated.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinico-epidemiological characteristics of men and women with a new diagnosis of chronic obstructive pulmonary disease: a database (SIDIAP) study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background The risk of developing Chronic Obstructive Pulmonary Disease (COPD), the associated comorbidities and response to bronchodilators might differ in men and women. The objective of this study was to determine the prevalence of COPD and the clinic-epidemiological characteristics of primary care patients with COPD according to gender. Methods This is a cross-sectional study using electronic healthcare records Catalonia (Spain), during the 01/01/2012–31/12/2017 period. Patients from the SIDIAP database (System for the Development of Research in Primary Care) were included (5,800,000 patients registered in 279 primary care health centres). Clinic-demographic characteristics, comorbidities and blood tests results were collected for each patient. Adjusted OR (ORa) with logistic regression methods were used to determine variables associated with men and women. Results From an initial sample of 800,899 people, 24,135 (3%) were considered COPD patients, and 22.9%were women. The most common risk factors in women were bronchiectasis (ORa = 20.5, SD = 19.5–21.6), age > 71 years (ORa = 18.8; SD = 17.3–20.5), cor pulmonale (ORa = 5.2; SD = 4.3–6.7) and lung cancer (ORa = 3.6, SD = 3.2–4.0). Men and women presented the same comorbidities, though the strength of association was different for each gender. Conclusions Patients suffering high comorbidity rates. Comorbidities are similar in men and women, although the strength of association varies according to gender. Women are more susceptible to the harmful effects of smoking and present a higher proportion of bronchiectasis and OSAS.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In the Vallès region of Catalonia, the prevalence of COPD using the criteria of the British Thoracic Society was 7.2% (10.4% in men and 4.1% in women) [ 5 ]. A recent study conducted by our group in the population of Lleida (Catalonia) showed a prevalence of 14.5% (16.1% in men and 12.3% in women) [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Clinico-epidemiological characteristics of men and women with a new diagnosis of chronic obstructive pulmonary disease: a database (SIDIAP) study

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Airway cell damage in COPD is largely attributed to oxidative and carbonyl stress [ 128 , 129 ]. Oxidative stress occurs when free radical exposure is able to suppress antioxidant defenses.…”

Section: Chronic Obstructive Pulmonary Diseasementioning

confidence: 99%

The ER Stress/UPR Axis in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

Aghaei

Dastghaib

Aftabi

et al. 2020

Life

View full text Add to dashboard Cite

Cellular protein homeostasis in the lungs is constantly disrupted by recurrent exposure to various external and internal stressors, which may cause considerable protein secretion pressure on the endoplasmic reticulum (ER), resulting in the survival and differentiation of these cell types to meet the increased functional demands. Cells are able to induce a highly conserved adaptive mechanism, known as the unfolded protein response (UPR), to manage such stresses. UPR dysregulation and ER stress are involved in numerous human illnesses, such as metabolic syndrome, fibrotic diseases, and neurodegeneration, and cancer. Therefore, effective and specific compounds targeting the UPR pathway are being considered as potential therapies. This review focuses on the impact of both external and internal stressors on the ER in idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) and discusses the role of the UPR signaling pathway activation in the control of cellular damage and specifically highlights the potential involvement of non-coding RNAs in COPD. Summaries of pathogenic mechanisms associated with the ER stress/UPR axis contributing to IPF and COPD, and promising pharmacological intervention strategies, are also presented.

show abstract

“…Las estimaciones sugieren que la proporción de fumadores mayores de 40 años no diagnosticados es de aproximadamente 1 de cada 5 (8) . Este problema crece cuando se considera que la EPOC aumenta como parte de los procesos naturales (por ejemplo, el envejecimiento) o el estilo de vida asociado con otros riesgos cardiovasculares (hipertensión, diabetes mellitus, dislipidemia) (9,10) . Actualmente, el subdiagnóstico en países de América Latina llega al 77 % (11) y en Colombia se estimó en el 63 % en el estudio PUMA (12) .…”

Section: Introductionunclassified

La evaluación con el cuestionario COPD-PS y el dispositivo portátil Vitalograph COPD - 6 como estrategia para el diagnóstico temprano de la EPOC en la atención primaria

García-Ortiz

Jiménez

Quijano-Almeida

2019

Iatreia

View full text Add to dashboard Cite

Objetivo: evaluar el uso del cuestionario COPD-PS y el dispositivo portátil Vitalograph COPD-6, como estrategia para el diagnóstico temprano de la enfermedad pulmonar obstructiva crónica (EPOC) en dos unidades de atención primaria de la empresa social del estado (E.S.E): Metrosalud, Medellín-Colombia en 2017. Métodos: estudio transversal de detección temprana de la EPOC, en personas mayores de 35 años sin diagnóstico previo de la enfermedad u otras complicaciones respiratorias subyacentes, a las cuales se les aplicó la prueba de tamizaje de COPD-PS para identificar factores de riesgo respiratorio y, posteriormente, la prueba de volumen espiratorio forzado (VEF1/VEF6) con el dispositivo portátil Vitalograph COPD-6. Resultados: de 1.485 pruebas de tamizaje COPD-PS, 198 presentaron un puntaje igual o superior a 4, por lo que se les realizó la prueba con el dispositivo Vitalograph. De los cuales, 147 (74,2 %) resultaron positivos. Discusión: el subregistro de la EPOC se describe actualmente como un grave problema mundial. El uso del cuestionario COPD-PS para la identificación de pacientes con factores de riesgo y del Vitalograph COPD-6 como prueba de función pulmonar, pueden ser herramientas útiles para implementar una estrategia efectiva en la reducción del subregistro de la EPOC.

show abstract

Prevalence of chronic obstructive pulmonary disease (COPD) not diagnosed in a population with cardiovascular risk factors

Cited by 3 publications

References 25 publications

Clinico-epidemiological characteristics of men and women with a new diagnosis of chronic obstructive pulmonary disease: a database (SIDIAP) study

Clinico-epidemiological characteristics of men and women with a new diagnosis of chronic obstructive pulmonary disease: a database (SIDIAP) study

The ER Stress/UPR Axis in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

La evaluación con el cuestionario COPD-PS y el dispositivo portátil Vitalograph COPD - 6 como estrategia para el diagnóstico temprano de la EPOC en la atención primaria

Contact Info

Product

Resources

About